JP2017504570A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017504570A5 JP2017504570A5 JP2016534640A JP2016534640A JP2017504570A5 JP 2017504570 A5 JP2017504570 A5 JP 2017504570A5 JP 2016534640 A JP2016534640 A JP 2016534640A JP 2016534640 A JP2016534640 A JP 2016534640A JP 2017504570 A5 JP2017504570 A5 JP 2017504570A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- tauopathy
- composition according
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361909965P | 2013-11-27 | 2013-11-27 | |
| US61/909,965 | 2013-11-27 | ||
| PCT/US2014/067360 WO2015081085A2 (en) | 2013-11-27 | 2014-11-25 | Methods of treating a tauopathy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017504570A JP2017504570A (ja) | 2017-02-09 |
| JP2017504570A5 true JP2017504570A5 (enExample) | 2017-09-28 |
| JP6629201B2 JP6629201B2 (ja) | 2020-01-15 |
Family
ID=52232410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016534640A Expired - Fee Related JP6629201B2 (ja) | 2013-11-27 | 2014-11-25 | タウオパチーの処置方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20160289309A1 (enExample) |
| EP (1) | EP3074420A2 (enExample) |
| JP (1) | JP6629201B2 (enExample) |
| CN (2) | CN105899230B (enExample) |
| BR (1) | BR112016010454A2 (enExample) |
| CA (1) | CA2931396C (enExample) |
| EA (1) | EA038994B1 (enExample) |
| MX (2) | MX384909B (enExample) |
| WO (1) | WO2015081085A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2885010T1 (sl) * | 2012-08-16 | 2020-07-31 | Ipierian, Inc. | Metode zdravljenja tauopatije |
| US12024568B2 (en) | 2012-09-13 | 2024-07-02 | Cornell University | Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies |
| US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| CA2902026C (en) | 2013-03-13 | 2023-08-29 | Prothena Biosciences Limited | Tau immunotherapy |
| CN105939722A (zh) | 2014-02-14 | 2016-09-14 | 伊皮埃里安股份有限公司 | Tau肽，抗Tau抗体，及其使用方法 |
| UA126272C2 (uk) | 2015-06-05 | 2022-09-14 | Дженентек, Інк. | Антитіло проти тау-білка та спосіб його застосування |
| WO2017100632A1 (en) * | 2015-12-11 | 2017-06-15 | Arizona Board Of Regents On Behalf Of Arizona State University | Human alzheimer's disease and traumatic brain injury associated tau variants as biomarkers and methods of use thereof |
| DK3452507T3 (da) | 2016-05-02 | 2022-11-14 | Prothena Biosciences Ltd | Tau-immunoterapi |
| SG11201808434WA (en) | 2016-05-02 | 2018-10-30 | Prothena Biosciences Ltd | Antibodies recognizing tau |
| MX2019006334A (es) | 2016-12-07 | 2019-08-01 | Genentech Inc | Anticuerpos antitau y métodos de uso. |
| CA3045294A1 (en) | 2016-12-07 | 2018-06-14 | Genentech, Inc. | Anti-tau antibodies and methods of use |
| JP2020508054A (ja) | 2017-02-17 | 2020-03-19 | デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 抗タウ抗体及びその使用方法 |
| BR112019022906A2 (pt) | 2017-05-02 | 2020-05-26 | Prothena Biosciences Limited | Anticorpos que reconhecem tau |
| US20190135905A1 (en) * | 2017-06-16 | 2019-05-09 | Bristol-Myers Squibb Company | Compositions and methods for treating tauopathies |
| JP2020529394A (ja) * | 2017-06-16 | 2020-10-08 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | タウオパチーを治療するための組成物及び方法 |
| CA3131531A1 (en) | 2019-03-03 | 2020-09-10 | Prothena Biosciences Limited | Antibodies recognizing tau |
| GB202010652D0 (en) * | 2020-07-10 | 2020-08-26 | Wista Lab Ltd | Anti-tau antibodies |
| CN115607684A (zh) * | 2021-07-15 | 2023-01-17 | 华中科技大学 | 一种内耳药物纳米载体及其应用 |
| KR20240118915A (ko) * | 2021-11-03 | 2024-08-05 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 항-타우 항체 조성물, 투여 형태 및 방법 |
| WO2025196217A1 (en) * | 2024-03-21 | 2025-09-25 | UCB Biopharma SRL | Treatment of tauopathies with tau-binding antibodies |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4866132A (en) | 1986-04-17 | 1989-09-12 | The Research Foundation Of State University Of New York | Novel radiopaque barium polymer complexes, compositions of matter and articles prepared therefrom |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| AU612370B2 (en) | 1987-05-21 | 1991-07-11 | Micromet Ag | Targeted multifunctional proteins |
| US5256334A (en) | 1988-09-08 | 1993-10-26 | The Research Foundation Of The State University Of New York | Homogeneous radiopaque polymer-organobismuth composites |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| ATE181571T1 (de) | 1991-09-23 | 1999-07-15 | Medical Res Council | Methoden zur herstellung humanisierter antikörper |
| JPH07501451A (ja) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | 多価抗原結合タンパク質 |
| US5346981A (en) | 1993-01-13 | 1994-09-13 | Miles Inc. | Radiopaque polyurethanes |
| CA2115811A1 (en) | 1993-02-17 | 1994-08-18 | Claus Krebber | A method for in vivo selection of ligand-binding proteins |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5625048A (en) | 1994-11-10 | 1997-04-29 | The Regents Of The University Of California | Modified green fluorescent proteins |
| AU4188196A (en) | 1994-12-22 | 1996-07-10 | Nissan Chemical Industries Ltd. | Organobismuth derivatives and process for producing the same |
| US5958713A (en) | 1995-01-31 | 1999-09-28 | Novo Nordisk A/S | Method of detecting biologically active substances by using green fluorescent protein |
| US5670477A (en) | 1995-04-20 | 1997-09-23 | Joseph F. Poduslo | Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents |
| US5968738A (en) | 1995-12-06 | 1999-10-19 | The Board Of Trustees Of The Leland Stanford Junior University | Two-reporter FACS analysis of mammalian cells using green fluorescent proteins |
| US6020192A (en) | 1996-01-18 | 2000-02-01 | University Of Florida | Humanized green fluorescent protein genes and methods |
| US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
| JP4162267B2 (ja) | 1996-08-27 | 2008-10-08 | カイロン コーポレイション | Ｎｅｉｓｓｅｒｉａ ｍｅｎｉｎｇｉｔｉｄｉｓ血清型Ｂ複合糖質およびその使用法 |
| US5976796A (en) | 1996-10-04 | 1999-11-02 | Loma Linda University | Construction and expression of renilla luciferase and green fluorescent protein fusion genes |
| TW371617B (en) | 1996-10-09 | 1999-10-11 | Of Animal And Plant Health Inspection And Quarantine Council Of Agriculture Executive Yuan Bureau | Method to transplant GFP into autographa californica multiple nuclear polyhedrosis virus for inflicting pest in an attempt to detect and flow up it existence and to improve life span against UV |
| AR014621A1 (es) | 1997-12-12 | 2001-03-28 | Macromed Inc | Un poli (etilenglicol) con forma de estrella, heterofuncional, biocompatible, metodo para su obtencion y metodo para conjugarlo con una proteina |
| US5985577A (en) | 1998-10-14 | 1999-11-16 | The Trustees Of Columbia University In The City Of New York | Protein conjugates containing multimers of green fluorescent protein |
| KR101699142B1 (ko) | 2004-06-18 | 2017-01-23 | 암브룩스, 인코포레이티드 | 신규 항원-결합 폴리펩티드 및 이의 용도 |
| US20090016959A1 (en) | 2005-02-18 | 2009-01-15 | Richard Beliveau | Delivery of antibodies to the central nervous system |
| US8741260B2 (en) | 2005-10-07 | 2014-06-03 | Armagen Technologies, Inc. | Fusion proteins for delivery of GDNF to the CNS |
| US8012936B2 (en) * | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| BRPI0923283A2 (pt) | 2008-12-05 | 2017-06-06 | Angiochem Inc | conjugados terapêuticos de peptídeo e usos dos mesmos |
| WO2010144711A2 (en) * | 2009-06-10 | 2010-12-16 | New York University | Immunological targeting of pathological tau proteins |
| CA2772379C (en) * | 2009-08-28 | 2019-09-24 | Rakez Kayed | Antibodies that bind tau oligomers |
| EA201290194A1 (ru) * | 2009-11-06 | 2013-04-30 | Дзе Дж. Дейвид Гладстоун Инститьютс | Способы и композиции для модулирования уровня тау-полипептида |
| EP2625198B1 (en) * | 2010-10-07 | 2015-07-22 | AC Immune S.A. | Antibodies recognising phospho-tau |
| US8940272B2 (en) * | 2010-10-11 | 2015-01-27 | University Of Zurich | Human anti-tau antibodies |
| GB201112056D0 (en) * | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
| SG10201912964PA (en) * | 2011-09-19 | 2020-02-27 | Axon Neuroscience Se | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease |
| SI2885010T1 (sl) * | 2012-08-16 | 2020-07-31 | Ipierian, Inc. | Metode zdravljenja tauopatije |
-
2014
- 2014-11-25 WO PCT/US2014/067360 patent/WO2015081085A2/en not_active Ceased
- 2014-11-25 US US15/038,711 patent/US20160289309A1/en not_active Abandoned
- 2014-11-25 MX MX2016006356A patent/MX384909B/es unknown
- 2014-11-25 CN CN201480064675.0A patent/CN105899230B/zh not_active Expired - Fee Related
- 2014-11-25 CA CA2931396A patent/CA2931396C/en active Active
- 2014-11-25 JP JP2016534640A patent/JP6629201B2/ja not_active Expired - Fee Related
- 2014-11-25 EA EA201690898A patent/EA038994B1/ru unknown
- 2014-11-25 CN CN202010377028.2A patent/CN111569063A/zh active Pending
- 2014-11-25 EP EP14820979.4A patent/EP3074420A2/en not_active Withdrawn
- 2014-11-25 BR BR112016010454A patent/BR112016010454A2/pt not_active Application Discontinuation
-
2016
- 2016-05-16 MX MX2021008755A patent/MX2021008755A/es unknown
-
2019
- 2019-04-29 US US16/398,097 patent/US20200102375A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017504570A5 (enExample) | ||
| JP2016503065A5 (enExample) | ||
| AR104875A1 (es) | Anticuerpos anti-tau y métodos de uso | |
| Dunning et al. | Can Parkinson's disease pathology be propagated from one neuron to another? | |
| WO2014058924A3 (en) | Antibodies recognizing alpha-synuclein | |
| MX356800B (es) | Anticuerpo tau humanizado. | |
| NZ748983A (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof | |
| IL266911B1 (en) | Anti-tau antibodies and uses thereof in treating tauopathy, retaining or increasing cognitive memory capacity or slowing memory loss | |
| JP2017502920A5 (enExample) | ||
| JP2014502141A5 (enExample) | ||
| JP2018519810A5 (enExample) | ||
| JP2018505651A5 (enExample) | ||
| JP2017532288A5 (enExample) | ||
| MX354662B (es) | Anticuerpos fosfoespecificos que reconocen la tau. | |
| NZ739181A (en) | Anti-pyroglutamated amyloid beta humanized antibodies | |
| AU2017291414B2 (en) | Anti-N3pGLu amyloid beta peptide antibodies and uses thereof | |
| WO2018175752A8 (en) | Optimized antibody compositions for treatment of ocular disorders | |
| IL225568A (en) | Phospho-specific antibodies for tau detection | |
| MX2021014274A (es) | Moleculas de union anti-tdp-43 y usos de las mismas. | |
| RU2017103446A (ru) | УЛУЧШЕННЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Аβ-ПРОТОФИБРИЛЛЫ | |
| WO2014204816A3 (en) | Method for assessing protein identity and stability | |
| WO2014160871A8 (en) | Methods and agents for treating alzheimer's disease | |
| Kroksveen et al. | Cerebrospinal fluid proteomics in multiple sclerosis | |
| JP2018535921A5 (enExample) | ||
| WO2018089807A3 (en) | Anti-cd46 antibodies and methods of use |